JP2006524206A5 - - Google Patents

Download PDF

Info

Publication number
JP2006524206A5
JP2006524206A5 JP2006505223A JP2006505223A JP2006524206A5 JP 2006524206 A5 JP2006524206 A5 JP 2006524206A5 JP 2006505223 A JP2006505223 A JP 2006505223A JP 2006505223 A JP2006505223 A JP 2006505223A JP 2006524206 A5 JP2006524206 A5 JP 2006524206A5
Authority
JP
Japan
Prior art keywords
methyl
propyl
ethyl
dioxide
indole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006505223A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006524206A (ja
Filing date
Publication date
Priority claimed from GBGB0309221.0A external-priority patent/GB0309221D0/en
Application filed filed Critical
Publication of JP2006524206A publication Critical patent/JP2006524206A/ja
Publication of JP2006524206A5 publication Critical patent/JP2006524206A5/ja
Withdrawn legal-status Critical Current

Links

JP2006505223A 2003-04-23 2004-04-21 三環式インドール誘導体およびアルツハイマー病治療におけるそれらの使用法 Withdrawn JP2006524206A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0309221.0A GB0309221D0 (en) 2003-04-23 2003-04-23 Novel compounds
PCT/EP2004/004244 WO2004094430A1 (en) 2003-04-23 2004-04-21 Tricyclic indole derivatives and their use in the treatment of alzheimer’s disease

Publications (2)

Publication Number Publication Date
JP2006524206A JP2006524206A (ja) 2006-10-26
JP2006524206A5 true JP2006524206A5 (enExample) 2007-05-10

Family

ID=9957152

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006505223A Withdrawn JP2006524206A (ja) 2003-04-23 2004-04-21 三環式インドール誘導体およびアルツハイマー病治療におけるそれらの使用法

Country Status (16)

Country Link
US (1) US20060229302A1 (enExample)
EP (1) EP1620438A1 (enExample)
JP (1) JP2006524206A (enExample)
KR (1) KR20050111797A (enExample)
CN (1) CN1809573A (enExample)
BR (1) BRPI0409622A (enExample)
CA (1) CA2523291A1 (enExample)
CO (1) CO5700829A2 (enExample)
GB (1) GB0309221D0 (enExample)
IS (1) IS8135A (enExample)
MA (1) MA27674A1 (enExample)
MX (1) MXPA05011365A (enExample)
NO (1) NO20055442L (enExample)
RU (1) RU2005136370A (enExample)
WO (1) WO2004094430A1 (enExample)
ZA (1) ZA200508041B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05005649A (es) * 2002-11-27 2005-08-16 Elan Pharm Inc Ureas y carbamatos sustituidos.
GB0328900D0 (en) * 2003-12-12 2004-01-14 Glaxo Group Ltd Novel compounds
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
GB0411404D0 (en) * 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
US20070213368A1 (en) * 2004-09-21 2007-09-13 Kleinman Edward F N-ethyl hydroxyethylamine useful in treating cns conditions
GB0422766D0 (en) * 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
GB0422765D0 (en) * 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
GB0422755D0 (en) * 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
WO2006088705A1 (en) * 2005-02-14 2006-08-24 Wyeth Terphenyl guanidines as [beta symbol] -secretase inhibitors
GB0506562D0 (en) * 2005-03-31 2005-05-04 Glaxo Group Ltd Novel compounds
CA2604291A1 (en) 2005-04-08 2006-10-19 Comentis, Inc. Compounds which inhibit beta-secretase activity and methods of use thereof
US20090170830A1 (en) * 2005-08-03 2009-07-02 Nantermet Philippe G Tricyclic Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
US7745484B2 (en) 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
WO2007061670A1 (en) * 2005-11-21 2007-05-31 Amgen Inc. Beta-secretase modulators and methods of use
US7838676B2 (en) * 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
CL2008001500A1 (es) 2007-05-25 2008-12-26 Amgen Inc Compuestos derivados de hidroxietil amina sustituidas, moduladores de betasecretasa; proceso de preparacion de dichos c ompuestos; composicion farmaceutica que los comprende; y su uso para tratar un trastorno neurologico, tal como alzheimer, sindrome de down, demencia degenerativa, entre otros.
AU2008257145B2 (en) 2007-05-25 2011-11-10 Amgen Inc. Substituted hydroxyethyl amine compounds as Beta-secretase modulators and methods of use
RS51912B (sr) * 2007-07-27 2012-02-29 Sanofi DERIVATI 1,2,3,4-TETRAHIDROPIROLO(1,2-a)PIRAZIN-6-KARBOKSAMIDA I 2,3,4,5-TETRAHIDROPIROLO(1,2-a)(1,4)-DIAZEPIN-7-KARBOKSAMIDA NJIHOVO DOBIJANJE I TERAPEUTSKA PRIMENA
FR2919285B1 (fr) 2007-07-27 2012-08-31 Sanofi Aventis Derives de 1-oxo-isoindoline-4-carboxamides et de 1-oxo- 1,2,3,4-tetrahydroisoquinoleine-5-carboxamides, leur preparation et leur application en therapeutique.
FR2919289B1 (fr) * 2007-07-27 2009-09-04 Sanofi Aventis Sa Derives de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]- diazepine-7-carboxamides, leur preparation et leur application en therapeutique.
FR2919286A1 (fr) 2007-07-27 2009-01-30 Sanofi Aventis Sa Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique.
FR2919288B1 (fr) * 2007-07-27 2009-09-04 Sanofi Aventis Sa Derives de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6- carboxamides, leur preparation et leur application en therapeutique.
US9096541B2 (en) 2012-03-29 2015-08-04 Oklahoma Medical Research Foundation Inhibition of memapsin 1 cleavage in the treatment of diabetes
WO2019058393A1 (en) * 2017-09-22 2019-03-28 Jubilant Biosys Limited HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PAD
WO2019075358A1 (en) * 2017-10-13 2019-04-18 Ghosh Arun K BACE1 INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
US12043631B2 (en) 2017-10-13 2024-07-23 Purdue Research Foundation BACE1 inhibitors for the treatment of Alzheimer's disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU749281B2 (en) * 1997-02-04 2002-06-20 Regents Of The University Of California, The Nanomolar, non-peptide inhibitors of cathepsin D
US6207664B1 (en) * 1998-11-25 2001-03-27 Pfizer Inc. Squalene synthetase inhibitor agents
WO2002002506A2 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease

Similar Documents

Publication Publication Date Title
JP2006524206A5 (enExample)
RU2005136370A (ru) Трициклические индоловые производные и их применение в лечении болезни альцгеймера
JP7278359B2 (ja) Shp2の活性を阻害するための化合物および組成物
JP6738933B2 (ja) Rbポジティブ異常細胞増殖に対するhspc温存治療
JP2014513704A5 (enExample)
JP2018521017A5 (enExample)
KR20190041471A (ko) 케모카인 수용체 조절제 및 이의 용도
JP2010509366A5 (enExample)
JP2020531447A5 (enExample)
KR20170117578A (ko) 플루오르화 테트라히드로나프티리디닐 노난산 유도체 및 이의 용도
JP2014526501A5 (enExample)
JP2006510716A5 (enExample)
JP2011527683A5 (enExample)
TR201802093T4 (tr) Terapötik terapilerde kullanım için akt inhibitör bileşiği ve abirateron kombinasyonu.
CN106132403A (zh) 喷雾干燥制剂
JP2015519368A5 (enExample)
JP2018531987A5 (enExample)
CN108430475B (zh) 用于治疗慢性咳嗽的奥维匹坦
JP2018515563A (ja) 化合物
JP2013520420A5 (enExample)
JP2017525721A (ja) 認知欠損または認知障害に伴って進行する神経障害のおよび神経変性疾患の処置および予防のための製品
JP2007513913A5 (enExample)
RU2006124863A (ru) Трициклические производные индолгидроксиэтиламина и их применение при лечении болезни альцгеймера
JP2016508135A5 (enExample)
JP2011522849A5 (enExample)